U.S. markets open in 7 hours 46 minutes

Chiasma, Inc. (CHMA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7600-0.2400 (-6.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.0000
Bid0.0000 x 3200
Ask0.0000 x 2900
Day's Range3.7600 - 4.1000
52 Week Range2.7700 - 5.7400
Avg. Volume996,380
Market Cap237.81M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMay 04, 2022 - May 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CHMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Chiasma, Inc.
    EGRX: What does Argus have to say about EGRX?EAGLE PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $47.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    20 days agoArgus Research
View more
  • Simply Wall St.

    When Will Chiasma, Inc. (NASDAQ:CHMA) Breakeven?

    Chiasma, Inc. ( NASDAQ:CHMA ) is possibly approaching a major achievement in its business, so we would like to shine...

  • PR Newswire

    Pulmatrix appoints Director Anand Varadan

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021.

  • GlobeNewswire

    SHAREHOLDER ALERT: Halper Sadeh LLP Investigates RAVN, BOCH, ONEM, CHMA; Shareholders are Encouraged to Contact the Firm

    NEW YORK, July 24, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Raven Industries, Inc. (NASDAQ: RAVN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to CNH Industrial N.V. for $58.00 per share. If you are a Raven shareholder, click here to learn more about your rights and options. Bank of Commerce Holdings (NASDAQ: BOCH) concerning poten